Compare RRBI & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRBI | PRTC |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.7M | 464.3M |
| IPO Year | 2019 | N/A |
| Metric | RRBI | PRTC |
|---|---|---|
| Price | $88.40 | $16.88 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $67.00 | N/A |
| AVG Volume (30 Days) | ★ 39.1K | 4.0K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 28.89 | N/A |
| EPS | ★ 6.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $30.10 | N/A |
| P/E Ratio | $13.85 | ★ $8.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.33 | $13.30 |
| 52 Week High | $93.90 | $20.00 |
| Indicator | RRBI | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 54.00 | 46.19 |
| Support Level | $85.35 | $16.60 |
| Resistance Level | $92.74 | $18.10 |
| Average True Range (ATR) | 2.72 | 0.48 |
| MACD | -0.48 | -0.04 |
| Stochastic Oscillator | 57.39 | 35.26 |
Red River Bancshares Inc is the bank holding company for the red river bank. The principal business of the Bank is lending and accepting deposits from businesses, professionals, individuals, and public entities. The bank's primary deposit products are demand deposits, savings deposits, and time deposits. The bank maintains a diversified loan portfolio with a focus on commercial real estate (Owner Occupied and Non-Owner Occupied), one-to-four-family residential, commercial, and industrial loans, construction and development Loans, and others. also, provides Treasury Management Services, Private Banking Services, Brokerage Services, and Other Banking Services.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.